Analysis of variola and vaccinia virus neutralization assays for smallpox vaccines.
Possible smallpox reemergence drives research for third-generation vaccines that effectively neutralize variola virus. A comparison of neutralization assays using different substrates, variola and vaccinia (Dryvax and modified vaccinia Ankara [MVA]), showed significantly different 90% neutralization titers; Dryvax underestimated while MVA overestimated variola neutralization. Third-generation vaccines may rely upon neutralization as a correlate of protection.
National Center for Emerging and Zoonotic Infectious Diseases, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. Christine.Hughes@cdc.hhs.gov
SourceClinical and vaccine immunology : CVI 19:7 2012 Jul pg 1116-8
Pub Type(s)Comparative Study
Research Support, N.I.H., Extramural